At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 526 enrolled
Drug / intervention
GSK1838262 +1 moredrug
Likely dose
GSK1838262 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache
In Brief
A Phase 2 clinical trial evaluating GSK1838262 and Placebo for Migraine Disorders and Migraine. Completed, enrolled 526 participants across 59 sites in 2 countries.
Detailed Summary
Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk flexible titration period and then enter the 12 week maintenance period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders, Migraine
CountriesCanada, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionJun 2010
TodayJul 2026
First PostedAug 27, 2008
Enrollment StartAug 1, 2008
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.8 years ago
Interventions
GSK1838262drug
Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
Placebodrug
Placebo-control